Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 240 entries
Sorted by: Best Match Show Resources per page
Erratum to: Update on Management of Cancer-Related Cachexia.

Current oncology reports

Anderson LJ, Albrecht ED, Garcia JM.
PMID: 28293870
Curr Oncol Rep. 2017 Mar;19(3):22. doi: 10.1007/s11912-017-0595-4.

No abstract available.

Cite
Anderson LJ, Albrecht ED, Garcia JM. Erratum to: Update on Management of Cancer-Related Cachexia. Curr Oncol Rep. 2017;19(3):22doi: 10.1007/s11912-017-0595-4.
Anderson, L. J., Albrecht, E. D., & Garcia, J. M. (2017). Erratum to: Update on Management of Cancer-Related Cachexia. Current oncology reports, 19(3), 22. https://doi.org/10.1007/s11912-017-0595-4
Anderson, Lindsey J, et al. "Erratum to: Update on Management of Cancer-Related Cachexia." Current oncology reports vol. 19,3 (2017): 22. doi: https://doi.org/10.1007/s11912-017-0595-4
Anderson LJ, Albrecht ED, Garcia JM. Erratum to: Update on Management of Cancer-Related Cachexia. Curr Oncol Rep. 2017 Mar;19(3):22. doi: 10.1007/s11912-017-0595-4. PMID: 28293870.
Copy Download .nbib Format: NLM
On the classification of research.

Current oncology reports

DeVita VT.
PMID: 12354355
Curr Oncol Rep. 2002 Nov;4(6):453-4. doi: 10.1007/s11912-002-0054-7.

No abstract available.

Cite
DeVita VT. On the classification of research. Curr Oncol Rep. 2002;4(6):453-4doi: 10.1007/s11912-002-0054-7.
DeVita, V. T. (2002). On the classification of research. Current oncology reports, 4(6), 453-4. https://doi.org/10.1007/s11912-002-0054-7
DeVita, Vincent T. "On the classification of research." Current oncology reports vol. 4,6 (2002): 453-4. doi: https://doi.org/10.1007/s11912-002-0054-7
DeVita VT. On the classification of research. Curr Oncol Rep. 2002 Nov;4(6):453-4. doi: 10.1007/s11912-002-0054-7. PMID: 12354355.
Copy Download .nbib Format: NLM
CT screening for lung cancer.

Current oncology reports

Bevers TB.
PMID: 17991359
Curr Oncol Rep. 2007 Nov;9(6):501-2. doi: 10.1007/s11912-007-0070-8.

No abstract available.

Cite
Bevers TB. CT screening for lung cancer. Curr Oncol Rep. 2007;9(6):501-2doi: 10.1007/s11912-007-0070-8.
Bevers, T. B. (2007). CT screening for lung cancer. Current oncology reports, 9(6), 501-2. https://doi.org/10.1007/s11912-007-0070-8
Bevers, Therese B. "CT screening for lung cancer." Current oncology reports vol. 9,6 (2007): 501-2. doi: https://doi.org/10.1007/s11912-007-0070-8
Bevers TB. CT screening for lung cancer. Curr Oncol Rep. 2007 Nov;9(6):501-2. doi: 10.1007/s11912-007-0070-8. PMID: 17991359.
Copy Download .nbib Format: NLM
Variations on the CHOP regimen: I. Prospective study in the elderly with aggressive non-Hodgkin's lymphomas.

Current oncology reports

Portlock CS.
PMID: 15291977
Curr Oncol Rep. 2004 Sep;6(5):357.

No abstract available.

Cite
Portlock CS. Variations on the CHOP regimen: I. Prospective study in the elderly with aggressive non-Hodgkin's lymphomas. Curr Oncol Rep. 2004;6(5):357
Portlock, C. S. (2004). Variations on the CHOP regimen: I. Prospective study in the elderly with aggressive non-Hodgkin's lymphomas. Current oncology reports, 6(5), 357.
Portlock, Carol S. "Variations on the CHOP regimen: I. Prospective study in the elderly with aggressive non-Hodgkin's lymphomas." Current oncology reports vol. 6,5 (2004): 357.
Portlock CS. Variations on the CHOP regimen: I. Prospective study in the elderly with aggressive non-Hodgkin's lymphomas. Curr Oncol Rep. 2004 Sep;6(5):357. PMID: 15291977.
Copy Download .nbib Format: NLM
Clinical Trials Report.

Current oncology reports

Portlock CS.
PMID: 16954017
Curr Oncol Rep. 2006 Sep;8(5):355-357. doi: 10.1007/s11912-006-0057-x.

No abstract available.

Cite
Portlock CS. Clinical Trials Report. Curr Oncol Rep. 2006;8(5):355-357doi: 10.1007/s11912-006-0057-x.
Portlock, C. S. (2006). Clinical Trials Report. Current oncology reports, 8(5), 355-357. https://doi.org/10.1007/s11912-006-0057-x
Portlock, Carol S. "Clinical Trials Report." Current oncology reports vol. 8,5 (2006): 355-357. doi: https://doi.org/10.1007/s11912-006-0057-x
Portlock CS. Clinical Trials Report. Curr Oncol Rep. 2006 Sep;8(5):355-357. doi: 10.1007/s11912-006-0057-x. PMID: 16954017.
Copy Download .nbib Format: NLM
New antiangiogenic agents for renal cell carcinoma: bevacizumab.

Current oncology reports

Bukowski RM.
PMID: 14751083
Curr Oncol Rep. 2004 Mar;6(2):85-6. doi: 10.1007/s11912-004-0017-2.

No abstract available.

Cite
Bukowski RM. New antiangiogenic agents for renal cell carcinoma: bevacizumab. Curr Oncol Rep. 2004;6(2):85-6doi: 10.1007/s11912-004-0017-2.
Bukowski, R. M. (2004). New antiangiogenic agents for renal cell carcinoma: bevacizumab. Current oncology reports, 6(2), 85-6. https://doi.org/10.1007/s11912-004-0017-2
Bukowski, Ronald M. "New antiangiogenic agents for renal cell carcinoma: bevacizumab." Current oncology reports vol. 6,2 (2004): 85-6. doi: https://doi.org/10.1007/s11912-004-0017-2
Bukowski RM. New antiangiogenic agents for renal cell carcinoma: bevacizumab. Curr Oncol Rep. 2004 Mar;6(2):85-6. doi: 10.1007/s11912-004-0017-2. PMID: 14751083.
Copy Download .nbib Format: NLM
Letrozole in postmenopausal women after five years on tamoxifen.

Current oncology reports

Perez EA.
PMID: 14664758
Curr Oncol Rep. 2004 Jan;6(1):35. doi: 10.1007/s11912-996-0013-9.

No abstract available.

Cite
Perez EA. Letrozole in postmenopausal women after five years on tamoxifen. Curr Oncol Rep. 2004;6(1):35doi: 10.1007/s11912-996-0013-9.
Perez, E. A. (2004). Letrozole in postmenopausal women after five years on tamoxifen. Current oncology reports, 6(1), 35. https://doi.org/10.1007/s11912-996-0013-9
Perez, Edith A. "Letrozole in postmenopausal women after five years on tamoxifen." Current oncology reports vol. 6,1 (2004): 35. doi: https://doi.org/10.1007/s11912-996-0013-9
Perez EA. Letrozole in postmenopausal women after five years on tamoxifen. Curr Oncol Rep. 2004 Jan;6(1):35. doi: 10.1007/s11912-996-0013-9. PMID: 14664758.
Copy Download .nbib Format: NLM
Two regimens of docetaxel for metastatic breast cancer.

Current oncology reports

Seidman AD, Norton L.
PMID: 15610678
Curr Oncol Rep. 2005 Jan;7(1):7. doi: 10.1007/s11912-005-0016-y.

No abstract available.

Cite
Seidman AD, Norton L. Two regimens of docetaxel for metastatic breast cancer. Curr Oncol Rep. 2005;7(1):7doi: 10.1007/s11912-005-0016-y.
Seidman, A. D., & Norton, L. (2005). Two regimens of docetaxel for metastatic breast cancer. Current oncology reports, 7(1), 7. https://doi.org/10.1007/s11912-005-0016-y
Seidman, Andrew D, and Norton, Larry. "Two regimens of docetaxel for metastatic breast cancer." Current oncology reports vol. 7,1 (2005): 7. doi: https://doi.org/10.1007/s11912-005-0016-y
Seidman AD, Norton L. Two regimens of docetaxel for metastatic breast cancer. Curr Oncol Rep. 2005 Jan;7(1):7. doi: 10.1007/s11912-005-0016-y. PMID: 15610678.
Copy Download .nbib Format: NLM
Commentary: Implications of cancer managed as a "chronic illness".

Current oncology reports

Markman M.
PMID: 21221861
Curr Oncol Rep. 2011 Apr;13(2):90-1. doi: 10.1007/s11912-010-0148-6.

In an increasing number of settings it is appropriate to consider cancer as a very serious but also a chronic disease process. This commentary discusses a number of highly clinically relevant implications of this important evolution in the management...

Cite
Markman M. Commentary: Implications of cancer managed as a "chronic illness". Curr Oncol Rep. 2011;13(2):90-1doi: 10.1007/s11912-010-0148-6.
Markman, M. (2011). Commentary: Implications of cancer managed as a "chronic illness". Current oncology reports, 13(2), 90-1. https://doi.org/10.1007/s11912-010-0148-6
Markman, Maurie. "Commentary: Implications of cancer managed as a "chronic illness"." Current oncology reports vol. 13,2 (2011): 90-1. doi: https://doi.org/10.1007/s11912-010-0148-6
Markman M. Commentary: Implications of cancer managed as a "chronic illness". Curr Oncol Rep. 2011 Apr;13(2):90-1. doi: 10.1007/s11912-010-0148-6. PMID: 21221861.
Copy Download .nbib Format: NLM
Prescribing adjuvant letrozole to patients well after the completion of tamoxifen: a good idea?.

Current oncology reports

Fox KR.
PMID: 19080735
Curr Oncol Rep. 2009 Jan;11(1):6-7.

No abstract available.

Cite
Fox KR. Prescribing adjuvant letrozole to patients well after the completion of tamoxifen: a good idea?. Curr Oncol Rep. 2009;11(1):6-7
Fox, K. R. (2009). Prescribing adjuvant letrozole to patients well after the completion of tamoxifen: a good idea?. Current oncology reports, 11(1), 6-7.
Fox, Kevin R. "Prescribing adjuvant letrozole to patients well after the completion of tamoxifen: a good idea?." Current oncology reports vol. 11,1 (2009): 6-7.
Fox KR. Prescribing adjuvant letrozole to patients well after the completion of tamoxifen: a good idea?. Curr Oncol Rep. 2009 Jan;11(1):6-7. PMID: 19080735.
Copy Download .nbib Format: NLM
Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature.

Current oncology reports

Portlock CS.
PMID: 17915376
Curr Oncol Rep. 2007 Sep;9(5):371; discussion 371.

No abstract available.

Cite
Portlock CS. Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature. Curr Oncol Rep. 2007;9(5):371; discussion 371
Portlock, C. S. (2007). Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature. Current oncology reports, 9(5), 371; discussion 371.
Portlock, Carol S. "Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature." Current oncology reports vol. 9,5 (2007): 371; discussion 371.
Portlock CS. Enzastaurin, a targeted PKCBeta inhibitor, in relapsed or refractory DLBCL: a promising new strategy based on gene expression signature. Curr Oncol Rep. 2007 Sep;9(5):371; discussion 371. PMID: 17915376.
Copy Download .nbib Format: NLM
Treatment of advanced melanoma with immunological checkpoint block.

Current oncology reports

Margolin K.
PMID: 21938386
Curr Oncol Rep. 2011 Dec;13(6):430-2. doi: 10.1007/s11912-011-0195-7.

No abstract available.

Cite
Margolin K. Treatment of advanced melanoma with immunological checkpoint block. Curr Oncol Rep. 2011;13(6):430-2doi: 10.1007/s11912-011-0195-7.
Margolin, K. (2011). Treatment of advanced melanoma with immunological checkpoint block. Current oncology reports, 13(6), 430-2. https://doi.org/10.1007/s11912-011-0195-7
Margolin, Kim. "Treatment of advanced melanoma with immunological checkpoint block." Current oncology reports vol. 13,6 (2011): 430-2. doi: https://doi.org/10.1007/s11912-011-0195-7
Margolin K. Treatment of advanced melanoma with immunological checkpoint block. Curr Oncol Rep. 2011 Dec;13(6):430-2. doi: 10.1007/s11912-011-0195-7. PMID: 21938386.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 240 entries